MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure (HF) Therapeutics (THT) conference on Tuesday, March 21, 2023. These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).
Heavy selloff following top-line data from the BeAT-HF trial, that failed ot meet primary endpoint. Still, there was numerous secondary data that was positive.
NEW YORK--(BUSINESS WIRE)---- $CVRX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). CVRx investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cvrx. The investigation concerns whether CVRx violated federal securities laws. On February 21, 2023, CVRx announced that its BeAT-HF post-market phase trial for
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Stocks Trending Alert: CVRx, Inc. (NASDAQ:CVRX), Almaden Minerals Ltd. (AMEX:AAU) appeared first on Stocks Equity .
NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NYSE: CVRX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980. The investigation…
Gainers Windtree Therapeutics Inc (NASDAQ: WINT ) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure." ECARX Holdings Inc. (NASDAQ: ECX ) gained 68% to $5.71. Terran Orbital Corporation (NYSE: LLAP ) surged 52% to $2.60 after the company annonced it has been awareded a $2.4 billion contract to design, build, and deploy 300 satellites for Rivada Space Networks. Hoth Therapeutics Inc (NASDAQ: HOTH ) shares rose 34.3% to $2.6613 after dropping over 9% on Tuesday. Hoth Therapeutics recently entered into a service agreement with Shareholder Intelligence Services to investigate and report on potential illegal naked short selling activities of its stock. Intuitive Machines, Inc. (NASDAQ: LUNR ) jumped 27.4% to $48.26. Usio, Inc. (NASDAQ: USIO ) rose 26.3% to $2.21. Berry Corporation (NASDAQ: BRY ) gained 19.9% to $10.56 after reporting better-than-expected Q4 results.
Gainers: Intuitive Machines LUNR +219%.ECARX ECX +115%.Terran Orbital LLAP +86%.Windtree (WINT) +58%.CVRx CVRX +42%.Ocean Biomedical (OCEA) +35%.Legato Merger (SLND) +26%.TROOPS…
Hoth Therapeutics (HOTH) +35%. CVRx (CVRX) +21%. Quoin Pharmaceuticals (QNRX) -41%. Chemomab Therapeutics (CMMB) -12%.
A failed test is sometimes all it takes to send a stock diving, especially with healthcare stocks. For CVRx (NASDAQ:CVRX), a failed test meant a 60…
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE ) gained … Full story available on Benzinga.com
Ambrx Biopharma (AMAM) +35%. Meihua International Medical Technologies (MHUA) +27%. Aileron Therapeutics (ALRN) -35%. CVRx (CVRX) -29%.
CVRx (CVRX) lost ~34% pre-market Tuesday after announcing that its post-market phase trial for FDA-cleared heart failure therapy Barostim did not reach main goal. Read the full story here.
CVRx had its target price upped by research analysts at JPMorgan Chase & Co. from $17.00 to $18.00 in a research report issued on Friday, Benzinga reports. The firm presently…
In last trading session, CVRx Inc. (NASDAQ:CVRX) saw 0.46 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $14.79 trading at $0.42 or 2.92% at ring of the bell on the day assigns it a market valuation of $295.65M. That closing price of CVRX’s stock is at … CVRx Inc. (NASDAQ:CVRX) Has Recovered 68.9% So Far, But Another -48.75% Loss Cannot Be Ruled Out Read More »
Inozyme Pharma (INZY) +20%. CVRx (CVRX) +10%. Nemaura Medical NMRD -41%. Marker Therapeutics (MRKR) -11%.
CVRx, Inc. (NASDAQ:NASDAQ:CVRX) Q4 2022 Earnings Conference Call January 26, 2023 5:30 PM ETCompany ParticipantsMike Vallie - Westwicke, ICR CompanyNadim Yared - President and Chief…
CVRx press release (CVRX): Q4 GAAP EPS of -$0.51 beats by $0.05.Revenue of $7.18M (+96.2% Y/Y) beats by $0.2M.Q1 2023 Outlook: The Company expects to report total revenue between…